Hans Edgar Bishop - 16 Jun 2021 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Director
Signature: /s/ Heather D. Turner, as Attorney-in-fact
Issuer symbol: LYEL
Transactions as of: 16 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 16 Jun 2021, 19:12:40 UTC
Next filing: 23 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LYEL	Common Stock						3,000,000	16 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LYEL	Series A Convertible Preferred Stock							16 Jun 2021	Common Stock	546,806	$1.83	Direct	F2
holding	LYEL	Option (right to buy)							16 Jun 2021	Common Stock	1,163,038	$0.1000	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/4 of the shares vested on August 1, 2019, with the remaining shares to vest in equal monthly installments over the following thirty-six months.
F2	The Series A Convertible Preferred Stock is convertible at any time, at the Reporting Person's election, has no expiration date, and will automatically convert to shares of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-1 basis.
F3	1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.